Compare LEE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | SCYX |
|---|---|---|
| Founded | 1890 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 26.3M |
| IPO Year | N/A | 2014 |
| Metric | LEE | SCYX |
|---|---|---|
| Price | $5.24 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 88.4K | ★ 371.4K |
| Earning Date | 02-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | $2,932,000.00 |
| Revenue This Year | $5.48 | $170.77 |
| Revenue Next Year | N/A | $286.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $0.57 |
| 52 Week High | $15.15 | $1.31 |
| Indicator | LEE | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 55.71 |
| Support Level | $4.60 | $0.63 |
| Resistance Level | $5.33 | $0.68 |
| Average True Range (ATR) | 0.43 | 0.03 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 78.74 | 60.52 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.